The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

A new study from Karolinska Institutet, published in Nature Communications, reveals that cyclin-dependent kinases (CDK) promote DNA replication licensing in human cells by relieving inhibitory signals ...

Clinical and Preclinical Activity of EGFR Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer Harboring BRAF Class 3 Mutations This was a phase II multicenter trial in which refractory solid ...

Trial in progress: First-in-human study of PFL-721/STX-721 in participants with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations. This is an ASCO ...

Andrés Aguilera's laboratory, in collaboration with that of Ralf Wellinger (both professors in the Department of Genetics at the University of Seville in CABIMER) and with PharmaMAR, has identified ...

Researchers have identified two natural compounds, patulin and xestoquinol, as new inhibitors of the enzyme topoisomerase 1, a key element in the correct functioning of DNA. The finding, published in ...

If you are anything like us, whenever you plan a journey, you spend a remarkable amount of time thinking about the start and ...